Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImClone Systems and Bristol-Myers Squibb have established an agreement with Merck KGaA for the co-development and co-commercialization of cancer drug Erbitux in Japan.
Subscribe to our email newsletter
Under the terms of the agreement, ImClone Systems, Bristol-Myers Squibb and Merck will develop Erbitux for the treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC), as well as for the treatment of any other cancers, the parties agree to pursue.
Bristol-Myers Squibb and Merck KGaA will utilize their respective sales forces in Japan, and the three companies will share profits/losses realized as a result of the agreement. Merck Serono Japan will distribute the product and record the sales for the collaboration.
John Johnson, CEO of Imclone Systems, said: “We are pleased to have established this agreement with our Erbitux partners Bristol-Myers Squibb and Merck KGaA. Doing so puts the companies in a solid position to make Erbitux available to EGFR-expressing metastatic colorectal cancer patients in Japan upon a final decision from Japanese regulatory officials.”